The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...

Specifically, in the PRRT-naive cohort, the ORR reached 60%, while 34.1% of patients showed stable disease. Combining these ...

Dr. Mary Maluccio discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 ...

A panelist discusses how data from the DeLLphi-304 trial position tarlatamab as a potential new standard for relapsed ...

Jaume Capdevila, MD, Vall d'Hebron Hospital, discusses the final analysis of the phase 3 COMPETE trial (NCT03049189). Data ...

Panelists discuss current frontline therapeutic strategies for advanced melanoma, highlighting the rationale and evolution of ...

A panelist discusses how proactive management of CRS and ICANS supports safe community use of DLL3-targeted therapy.

An exosome-based treatment of glioblastoma multiforme (GBM) has received orphan drug designation from the FDA. 1 Exousia AI, ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

Somatostatin analogs (SSAs) like octreotide LAR and lanreotide are essential in managing NETs. Standard practice involves ...

A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell ...

At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...